Shares of US-based Rite Aid were down on Wednesday afternoon after media reports that US antitrust regulators may sue to stop its takeover by Walgreens. Bloomberg, citing trade publication Capitol Forum, said that the US Federal Trade Commission was considering a lawsuit to block the proposed merger.
The proposed deal has apparently hit turbulence in Washington since it was announced back in 2015. At that time, Walgreens said it would pay $9 a share, but earlier this year Walgreens said it would now pay just $6.50-$7 a share, valuing the deal between $6.82bn and $7.35bn.
Full Content: Bloomberg
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Spain’s Financial Regulator Awaits Antitrust Decision on BBVA’s Hostile Bid for Sabadell
Dec 5, 2024 by
CPI
RealPage Seeks Dismissal of DOJ Antitrust Suit, Citing Legal Flaws
Dec 5, 2024 by
CPI
EU Competition Chief Signals Potential Google Breakup Amid Big Tech Scrutiny
Dec 5, 2024 by
CPI
Turkey Closes Antitrust Probe into Meta’s Threads-Instagram Practices
Dec 5, 2024 by
CPI
Major Overhaul of New Zealand Competition Laws Announced
Dec 5, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Moats & Entrenchment
Nov 29, 2024 by
CPI
Assessing the Potential for Antitrust Moats and Trenches in the Generative AI Industry
Nov 29, 2024 by
Allison Holt, Sushrut Jain & Ashley Zhou
How SEP Hold-up Can Lead to Entrenchment
Nov 29, 2024 by
Jay Jurata, Elena Kamenir & Christie Boyden
The Role of Moats in Unlocking Economic Growth
Nov 29, 2024 by
CPI
Overcoming Moats and Entrenchment: Disruptive Innovation in Generative AI May Be More Successful than Regulation
Nov 29, 2024 by
Simon Chisholm & Charlie Whitehead